Urolog. pro Praxi, 2006; 4: 180-181 [Interní Med. 2006; 8(1): 42-43]

Epidemiologie a klasifikace chronického onemocnění ledvin

prof. MUDr. Vladimír Tesař DrSc1, doc. MUDr. Vladimír Tesař DrSc2
1 Klinika nefrologie 1. LF UK a VFN, Praha
2 I. interní klinika 1. LF UK a VFN Praha

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař V, Tesař V. Epidemiologie a klasifikace chronického onemocnění ledvin. Urol. praxi. 2006;7(4):180-181.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816. Go to original source... Go to PubMed...
    2. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. Am J Kidney Dis 2003; 41: 1-12. Go to original source... Go to PubMed...
    3. de Leeuw PW, Thijs L, Birkenhager WH et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213-2222. Go to original source... Go to PubMed...
    4. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486-2497. Go to PubMed...
    5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002; 287: 356-359. Go to original source... Go to PubMed...
    6. Geluk CA, Asselbergs FW, Hillege HL et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND intervention trial. eur. Heart J 2005; 26: 1314-1320. Go to original source... Go to PubMed...
    7. Henry RMA, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The hoorn study. Kidney Int 2002; 62: 1402-1407. Go to original source... Go to PubMed...
    8. Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526. Go to original source... Go to PubMed...
    9. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1-S266.
    10. Kurella M, Lo JC, Chertow GM. Metabolic Syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140. Go to original source... Go to PubMed...
    11. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906. Go to original source... Go to PubMed...
    12. Mann JFE, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636. Go to original source... Go to PubMed...
    13. Ohmit SE, Flack JM, Peters RM et al. Longitudinal study of the national kidney foundations (NKF), Kidney early evaluation program (KEEP). J Am Soc Nephrol 2003; 14 (Suppl 2): 117-121. Go to original source... Go to PubMed...
    14. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001 12: 218-225. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.